Gene expression analysis reveals functional pathways of glatiramer acetate activation

Natural Naive CD4 + CD25 + CD127 low Regulatory T Cell (Treg) Development and Function Are Disturbed in Multiple Sclerosis Patients: Recovery of Memory Treg Homeostasis during Disease Progression

(2014) Koen Venken et al.   JOURNAL OF IMMUNOLOGY

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis

(2013) Anat Achiron et al.   DISEASE MARKERS

Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations

(2012) Petra Praksova et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

The glatiramoid class of immunomodulator drugs

(2009) Haim Varkony et al.   EXPERT OPINION ON PHARMACOTHERAPY

Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4+CD25+FOXP3+CD31+ T-cells in patients with multiple sclerosis

(2009) Juergen Haas et al.   JOURNAL OF NEUROIMMUNOLOGY